Intralytix receives funding from the Maryland Department of Commerce to advance AI - ML-driven phage manufacturing

Columbia, MD – February 25, 2026 – Intralytix, Inc., a global leader in bacteriophage technology, has been awarded a Maryland Manufacturing 4.0 grant to enhance its phage manufacturing capabilities through the adoption of advanced Industry 4.0 technologies. The company will expand its proprietary PhageEngine™ platform by integrating in silico “omics”-based biological data and establishing a comprehensive digital twin, Dr. Alexander "Sandro" Sulakvelidze, President & CEO of Intralytix.accelerating process optimization and reducing time-to-insight for the development of innovative phage-based solutions.

Intralytix’s work with bacteriophages – viruses that specifically target harmful bacteria - has broad applications across human and veterinary applications, nutritional supplementation, and food safety. The company’s Artificial Intelligence – Machine Learning (AI-/ML) - driven approach enables rapid development of targeted bacteriophage products, addressing antimicrobial resistance and providing natural, precision solutions to microbial challenges.

“This award supports our efforts to modernize and scale bacteriophage manufacturing,” said Dr. Alexander “Sandro” Sulakvelidze, President and CEO of Intralytix. “As the largest manufacturer of FDA-approved phages in the U.S., with 21 CFR 117 cGMP compliance and SQF certification, Intralytix already sets the standard for quality and compliance in phage production. Leveraging AI and machine learning through this grant will further enhance our phage manufacturing capabilities, improving efficiency, reproducibility, and innovation, while solidifying our leadership in delivering precision antimicrobial solutions across human and veterinary applications, food safety, and agricultural biotechnology”.

Bradley Anderson, VP of Logistics and Production at Intralytix and the driving force behind the company’s proprietary PhageSelector™, PhageEngine™, and PhageSeek™ platforms, added: “Intralytix’s Industry 4.0 strategy will integrate smart sensors, robotics, cloud platforms, automation, and digital twins to enhance phage production and manufacturing. This approach allows us to simulate, optimize, and scale processes faster than ever - continuing to position Bradley Anderson, VP of Production and Logistics at Intralytix, Inc.Intralytix at the forefront of next-generation biomanufacturing while maximizing impact for public health and food safety”.

The Maryland Manufacturing 4.0 program supports companies in adopting cutting-edge Industry 4.0 technologies to strengthen competitiveness, accelerate growth, and promote innovation in manufacturing.

About Intralytix, Inc.

Headquartered in Columbia, Maryland, Intralytix is the world’s leading developer of bacteriophage-based products for food safety, human health, veterinary applications, and environmental remediation. The company currently markets a range of FDA-cleared and USDA-approved phage products and maintains a robust pipeline of novel nutraceutical and therapeutic antimicrobial interventions targeting antibiotic-resistant and foodborne bacterial pathogens. For more information, please visit www.intralytix.com or contact:

Alexander Sulakvelidze
President & CEO
Intralytix, Inc.
asulakvelidze@intralytix.com
+1 (410) 625-2533